Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × Somatostatin × NET × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 6 Gastro-enteropancreatic neuroendocrine tumor 1 Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 5 Ipilimumab 3 Everolimus 3 lutetium Lu 177 dotatate 2 Temozolomide 2 Fluorodeoxyglucose F18 2 tivozanib 1 sintilimab 1 repotrectinib 1 pralsetinib 1 copper dotatate CU-64 1 cabozantinib 1 belinostat 1 avelumab 1 atezolizumab 1 Sunitinib 1 Somatostatin 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Etoposide 1 Drug Therapy 1 Copper 1 Cisplatin 1 Capecitabine 1 CTLA-4 Antigen 1 64Cu-DOTATATE 1 177Lu-octreotate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04464122 2025-04-03

REBORN

University of Roma La Sapienza

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡